Does the media favor JANX or ARCT?

In the previous week, Janux Therapeutics had 1 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 4 mentions for Janux Therapeutics and 3 mentions for Arcturus Therapeutics. Janux Therapeutics' average media sentiment score of 0.31 beat Arcturus Therapeutics' score of 0.18 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcturus Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ARCT or ANNX?

In the previous week, Arcturus Therapeutics had 1 more articles in the media than Annexon. MarketBeat recorded 3 mentions for Arcturus Therapeutics and 2 mentions for Annexon. Annexon's average media sentiment score of 0.86 beat Arcturus Therapeutics' score of 0.18 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Annexon 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ORIC or ARCT?

In the previous week, Arcturus Therapeutics had 1 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 3 mentions for Arcturus Therapeutics and 2 mentions for Oric Pharmaceuticals. Arcturus Therapeutics' average media sentiment score of 0.18 beat Oric Pharmaceuticals' score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcturus Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Arcturus Therapeutics (ARCT) Competitors

$7.30 -0.74 (-9.20%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$7.54 +0.24 (+3.22%)

As of 06/5/2026 06:49 PM Eastern

Compare

ARCT vs. JANX, ANNX, XNCR, ORIC, and DRUG

Should you buy Arcturus Therapeutics stock or one of its competitors? MarketBeat compares Arcturus Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arcturus Therapeutics include Janux Therapeutics (JANX), Annexon (ANNX), Xencor (XNCR), Oric Pharmaceuticals (ORIC), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry.

How does Arcturus Therapeutics compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by company insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Janux Therapeutics has a beta of 2.53, suggesting that its share price is 153% more volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.36, suggesting that its share price is 136% more volatile than the broader market.

Arcturus Therapeutics has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	81.47	-$113.62M	-$1.84	N/A
Arcturus Therapeutics	$82.03M	2.53	-$65.78M	-$2.81	N/A

Janux Therapeutics has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -143.80%. Janux Therapeutics' return on equity of -12.93% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-12.93%	-12.23%
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%

In the previous week, Janux Therapeutics had 1 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 4 mentions for Janux Therapeutics and 3 mentions for Arcturus Therapeutics. Janux Therapeutics' average media sentiment score of 0.31 beat Arcturus Therapeutics' score of 0.18 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcturus Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Janux Therapeutics presently has a consensus target price of $45.85, suggesting a potential upside of 243.16%. Arcturus Therapeutics has a consensus target price of $25.44, suggesting a potential upside of 248.55%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Arcturus Therapeutics is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.60
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Janux Therapeutics beats Arcturus Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Annexon?

Arcturus Therapeutics (NASDAQ:ARCT) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

Annexon has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -143.80%. Arcturus Therapeutics' return on equity of -36.55% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%
Annexon	N/A	-101.19%	-75.99%

In the previous week, Arcturus Therapeutics had 1 more articles in the media than Annexon. MarketBeat recorded 3 mentions for Arcturus Therapeutics and 2 mentions for Annexon. Annexon's average media sentiment score of 0.86 beat Arcturus Therapeutics' score of 0.18 indicating that Annexon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Annexon	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

94.5% of Arcturus Therapeutics shares are held by institutional investors. 17.8% of Arcturus Therapeutics shares are held by insiders. Comparatively, 10.3% of Annexon shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Arcturus Therapeutics has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	2.53	-$65.78M	-$2.81	N/A
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

Arcturus Therapeutics currently has a consensus target price of $25.44, suggesting a potential upside of 248.55%. Annexon has a consensus target price of $16.00, suggesting a potential upside of 202.46%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Arcturus Therapeutics is more favorable than Annexon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Arcturus Therapeutics has a beta of 2.36, suggesting that its share price is 136% more volatile than the broader market. Comparatively, Annexon has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market.

Summary

Arcturus Therapeutics beats Annexon on 13 of the 16 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Xencor?

Xencor (NASDAQ:XNCR) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

In the previous week, Arcturus Therapeutics had 3 more articles in the media than Xencor. MarketBeat recorded 3 mentions for Arcturus Therapeutics and 0 mentions for Xencor. Arcturus Therapeutics' average media sentiment score of 0.18 beat Xencor's score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Xencor	Neutral
Arcturus Therapeutics	Neutral

94.5% of Arcturus Therapeutics shares are owned by institutional investors. 5.1% of Xencor shares are owned by insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Xencor has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.36, indicating that its stock price is 136% more volatile than the broader market.

Xencor presently has a consensus price target of $24.50, indicating a potential upside of 108.16%. Arcturus Therapeutics has a consensus price target of $25.44, indicating a potential upside of 248.55%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Arcturus Therapeutics is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67

Arcturus Therapeutics has lower revenue, but higher earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	6.95	-$91.92M	-$2.29	N/A
Arcturus Therapeutics	$82.03M	2.53	-$65.78M	-$2.81	N/A

Arcturus Therapeutics has a net margin of -143.80% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%

Summary

Arcturus Therapeutics beats Xencor on 12 of the 17 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Arcturus Therapeutics has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Arcturus Therapeutics	$82.03M	2.53	-$65.78M	-$2.81	N/A

Oric Pharmaceuticals presently has a consensus target price of $19.36, suggesting a potential upside of 158.18%. Arcturus Therapeutics has a consensus target price of $25.44, suggesting a potential upside of 248.55%. Given Arcturus Therapeutics' higher possible upside, analysts plainly believe Arcturus Therapeutics is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67

Oric Pharmaceuticals has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -143.80%. Oric Pharmaceuticals' return on equity of -35.33% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by company insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Arcturus Therapeutics had 1 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 3 mentions for Arcturus Therapeutics and 2 mentions for Oric Pharmaceuticals. Arcturus Therapeutics' average media sentiment score of 0.18 beat Oric Pharmaceuticals' score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcturus Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oric Pharmaceuticals has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.36, meaning that its stock price is 136% more volatile than the broader market.

Summary

Arcturus Therapeutics beats Oric Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Bright Minds Biosciences?

Arcturus Therapeutics (NASDAQ:ARCT) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are held by institutional investors. 17.8% of Arcturus Therapeutics shares are held by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Bright Minds Biosciences has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -143.80%. Bright Minds Biosciences' return on equity of -20.58% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%
Bright Minds Biosciences	N/A	-20.58%	-20.25%

In the previous week, Bright Minds Biosciences had 9 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 12 mentions for Bright Minds Biosciences and 3 mentions for Arcturus Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.18 beat Bright Minds Biosciences' score of 0.16 indicating that Arcturus Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Arcturus Therapeutics	Neutral
Bright Minds Biosciences	Neutral

Bright Minds Biosciences has lower revenue, but higher earnings than Arcturus Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	2.53	-$65.78M	-$2.81	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A

Arcturus Therapeutics has a beta of 2.36, meaning that its share price is 136% more volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.53, meaning that its share price is 653% less volatile than the broader market.

Arcturus Therapeutics currently has a consensus price target of $25.44, indicating a potential upside of 248.55%. Bright Minds Biosciences has a consensus price target of $143.83, indicating a potential upside of 108.45%. Given Arcturus Therapeutics' higher probable upside, research analysts clearly believe Arcturus Therapeutics is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

Arcturus Therapeutics and Bright Minds Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

Get Arcturus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARCT vs. The Competition

Export

Metric	Arcturus Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$207.49M	$3.34B	$6.68B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.55%
P/E Ratio	-2.60	18.85	24.03	23.62
Price / Sales	2.53	300.34	519.33	112.45
Price / Cash	N/A	116.33	42.23	54.60
Price / Book	0.97	6.51	9.73	6.35
Net Income	-$65.78M	$24.19M	$3.57B	$337.59M
7 Day Performance	-7.83%	-6.96%	-1.26%	-2.51%
1 Month Performance	-20.04%	-4.27%	0.82%	-0.69%
1 Year Performance	-42.92%	36.81%	24.09%	25.37%

Arcturus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARCT Arcturus Therapeutics	2.5418 of 5 stars	$7.30 -9.2%	$25.44 +248.6%	-38.7%	$207.49M	$82.03M	N/A	180	News Coverage
JANX Janux Therapeutics	3.2355 of 5 stars	$14.41 -1.2%	$45.85 +218.2%	-46.0%	$889.76M	$10M	N/A	30	News Coverage Positive News
ANNX Annexon	3.3397 of 5 stars	$5.58 +3.0%	$16.00 +186.7%	+107.5%	$888.03M	N/A	N/A	60	Positive News Gap Up High Trading Volume
XNCR Xencor	1.6361 of 5 stars	$11.80 -0.7%	$24.50 +107.6%	+29.1%	$880.81M	$97.36M	N/A	280	Positive News
ORIC Oric Pharmaceuticals	1.9595 of 5 stars	$8.98 +6.3%	$19.36 +115.6%	-18.1%	$874.72M	N/A	N/A	80	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARCT) was last updated on 6/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcturus Therapeutics (ARCT) Competitors

ARCT vs. JANX, ANNX, XNCR, ORIC, and DRUG

How does Arcturus Therapeutics compare to Janux Therapeutics?

Summary

How does Arcturus Therapeutics compare to Annexon?

Summary

How does Arcturus Therapeutics compare to Xencor?

Summary

How does Arcturus Therapeutics compare to Oric Pharmaceuticals?

Summary

How does Arcturus Therapeutics compare to Bright Minds Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT vs. The Competition

Arcturus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcturus Therapeutics (ARCT) Competitors

ARCT vs. JANX, ANNX, XNCR, ORIC, and DRUG

How does Arcturus Therapeutics compare to Janux Therapeutics?

Do insiders & institutionals have more ownership in JANX or ARCT?

Which has more risk and volatility, JANX or ARCT?

Which has stronger valuation & earnings, JANX or ARCT?

Is JANX or ARCT more profitable?

Does the media favor JANX or ARCT?

Do analysts prefer JANX or ARCT?

Summary

How does Arcturus Therapeutics compare to Annexon?

Is ARCT or ANNX more profitable?

Does the media refer more to ARCT or ANNX?

Do insiders and institutionals hold more shares of ARCT or ANNX?

Which has higher earnings & valuation, ARCT or ANNX?

Do analysts recommend ARCT or ANNX?

Which has more risk and volatility, ARCT or ANNX?

Summary

How does Arcturus Therapeutics compare to Xencor?

Does the media favor XNCR or ARCT?

Do insiders & institutionals believe in XNCR or ARCT?

Which has more volatility and risk, XNCR or ARCT?

Do analysts recommend XNCR or ARCT?

Which has stronger earnings and valuation, XNCR or ARCT?

Is XNCR or ARCT more profitable?

Summary

How does Arcturus Therapeutics compare to Oric Pharmaceuticals?

Which has stronger earnings and valuation, ORIC or ARCT?

Do analysts prefer ORIC or ARCT?

Is ORIC or ARCT more profitable?

Do insiders and institutionals hold more shares of ORIC or ARCT?

Does the media prefer ORIC or ARCT?

Which has more risk & volatility, ORIC or ARCT?

Summary

How does Arcturus Therapeutics compare to Bright Minds Biosciences?

Do institutionals & insiders believe in ARCT or DRUG?

Is ARCT or DRUG more profitable?

Does the media refer more to ARCT or DRUG?

Which has stronger earnings and valuation, ARCT or DRUG?

Which has more volatility and risk, ARCT or DRUG?

Do analysts rate ARCT or DRUG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT vs. The Competition

Arcturus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools